Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
News
Nature Biotechnology 25, 497–499 (1 May 2007) | doi:10.1038/nbt0507-497
Antisense|[mdash]|down, but not out
Abstract
Learning from past failures, could firms developing antisense drugs stage a comeback?
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
